Processing...
Clinical Trials for Melanoma
Search
Search
There are 157 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
157 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with unresectable stage IIIC–IV BRAF V600E–mutant melanoma (ECOG 0–2) receive vemurafenib (oral BRAF V600 inhibitor) combined with metformin (biguanide with AMPK/mTOR/tumor metabolism effects). Excludes prior vemurafenib or metformin intolerance; treatment is continuous 28-day cycles until progression or toxicity.
ClinicalTrials.gov ID: NCT01638676
TrialFetch AI summary: Adults with unresectable stage III/IV solid tumors (e.g., melanoma, BCC, SCC) refractory to prior anti–PD‑1/PD‑L1 therapy receive an oral, precision‑engineered live biotherapeutic (R‑5780) added to their ongoing PD‑1 pathway inhibitor. R‑5780 is designed to modulate gut–immune pathways to enhance anti‑tumor T‑cell responses and potentiate checkpoint inhibition; key exclusions include recent broad‑spectrum antibiotics, active infections, significant autoimmune disease, untreated brain mets, and >4 prior systemic therapies.
ClinicalTrials.gov ID: NCT06398418
TrialFetch AI summary: Enrolling HLA-A*02:01–positive adults with metastatic uveal melanoma involving the liver (≥1 measurable liver lesion), ECOG 0–1; Part 1 focuses on low–moderate hepatic burden and no prior systemic therapy in the metastatic setting, while Part 2 includes bulky liver-dominant disease (largest lesion >5 cm and/or ≥50% liver involvement) and allows up to 2 prior systemic/liver-directed lines (excluding prior tebentafusp and prior chemoembolization). Patients receive weekly step-up tebentafusp-tebn (gp100/HLA-A*02:01–directed ImmTAC that redirects T cells via anti-CD3) alone or combined with hepatic immunoembolization plus GM-CSF (randomized vs tebentafusp alone in Part 1B), or sequential BCNU (carmustine) transarterial chemoembolization followed by tebentafusp in bulky disease (Part 2).
ClinicalTrials.gov ID: NCT06626516
TrialFetch AI summary: Eligible patients are adults with ECOG 0–1, HLA-A*02:01–positive metastatic uveal melanoma with liver-dominant disease (≤50% liver replacement) and at least one measurable hepatic lesion, with significant extrahepatic disease largely excluded. Treatment is two sequential percutaneous hepatic perfusions delivering high-dose melphalan with extracorporeal hemofiltration 6–8 weeks apart, followed by up to 1 year of weekly tebentafusp (a gp100 peptide–HLA-directed TCR/anti-CD3 bispecific that redirects T cells to gp100-expressing melanoma cells), with additional PHP allowed on progression as standard of care.
ClinicalTrials.gov ID: NCT07276386
TrialFetch AI summary: Adults with unresectable stage III/IV or metastatic melanoma (cutaneous/acral; plus a cohort for mucosal or uveal), ECOG 0–1, progressed after at least one standard systemic therapy (e.g., anti–PD-1/L1; BRAF±MEK if BRAF V600-mutant), with an accessible lesion for harvest and stable treated brain metastases allowed. Patients undergo tumor resection for manufacturing, lymphodepleting cyclophosphamide/fludarabine, then a single infusion of autologous CD40L-augmented tumor-infiltrating lymphocytes (CD40 ligand signaling to enhance APC activation/costimulation) followed by short-course bolus aldesleukin (IL-2) support.
ClinicalTrials.gov ID: NCT06961357
TrialFetch AI summary: For adults with unresectable/metastatic melanoma with biopsy-confirmed liver metastasis who are systemic-treatment naïve in the metastatic setting (prior adjuvant anti–PD-1 and/or BRAF/MEK allowed if >6 months), this study combines liver-directed melphalan percutaneous hepatic perfusion via the HEPZATO KIT (temporary hepatic vascular isolation with extracorporeal filtration to limit systemic exposure) with fixed-dose Opdualag (nivolumab PD-1 blockade plus relatlimab LAG-3 blockade to enhance T-cell activation). It evaluates safety and preliminary systemic and hepatic antitumor activity.
ClinicalTrials.gov ID: NCT07281924
TrialFetch AI summary: This trial involves adults with unresectable or metastatic advanced solid tumors who have progressed on prior treatments or are candidates for pembrolizumab, combining pembrolizumab, which targets the PD-1 receptor to enhance immune response, with a personalized neoantigen peptide vaccine designed to stimulate an individualized immune attack against tumor-associated proteins.
ClinicalTrials.gov ID: NCT05269381
TrialFetch AI summary: This trial involves patients with advanced or metastatic solid tumors, such as melanoma and non-small cell lung cancer, who have had prior therapies, evaluating the safety and efficacy of Alintegimod, an integrin-targeting agent, combined with ipilimumab and nivolumab.
ClinicalTrials.gov ID: NCT06362369
TrialFetch AI summary: The trial is for adult patients with advanced or metastatic non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, or malignant melanoma who have no remaining standard treatment options, and it evaluates the safety, tolerability, and dosing of the investigational drug LB-LR1109, administered intravenously.
ClinicalTrials.gov ID: NCT06332755
TrialFetch AI summary: This trial evaluates a personalized multi-peptide neo-antigen vaccine combined with poly ICLC and the PD-1 inhibitor nivolumab in adult patients with advanced, treatment-resistant stage IIIC-IV melanoma, hormone receptor positive HER2-negative metastatic breast cancer, and stage III-IV non-small cell lung cancer, focusing on safety and immune response.
ClinicalTrials.gov ID: NCT05098210